Schedule 13G ownership disclosure
Apellis Pharmaceuticals Inc
Common Stock · CUSIP: 03753U106
Event date: 2026-01-31
- Filing-level shares
- 13,228,073
- Percent of class
- 10.5%
- BlackRock, Inc.
Shares: 13,228,073 · Class: 10.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0002012383-26-000899
- Form type
- SCHEDULE 13G
- Filer
- Apellis Pharmaceuticals, Inc.
- CIK
- CIK 1492422
- Filed
- Feb 06, 2026
- Reporting period
- Jan 31, 2026
- Description
- Schedule 13G beneficial ownership